Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jill Durrant"'
Autor:
Selina M. Luger, David I. Marks, Susan M. Richards, Letizia Foroni, Gordon W. Dewald, Mark R. Litzow, Hillard M. Lazarus, Adele K. Fielding, I. Jill Durrant, Martin S. Tallman, Georgina Buck, Anthony H. Goldstone, Jacob M. Rowe, Elisabeth Paietta, Ian M. Franklin, Anthony V. Moorman, Andrew McMillan, Peter H. Wiernik
Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) are limited. The UKALLXII/ECOG 2993 study evaluated the outcome of assigning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75fdffb428c20d97c365b80b3ee27f7f
https://ora.ox.ac.uk/objects/uuid:666c244b-6d06-4280-997f-d300ec3a0624
https://ora.ox.ac.uk/objects/uuid:666c244b-6d06-4280-997f-d300ec3a0624
Autor:
Hillard M. Lazarus, Georgina Buck, Susan M. Richards, Mark R. Litzow, R Chopra, Martin S. Tallman, Jacob M. Rowe, Jill Durrant, Peter H. Wiernik, Ian M. Franklin, Anthony H. Goldstone, H. Grant Prentice, Niculae Ciobanu, Alan Kenneth Burnett
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0c381cd355b28e2acaa436742d03106
https://ora.ox.ac.uk/objects/uuid:971d5bfc-5a3a-4ea9-a4f4-e97b444243e1
https://ora.ox.ac.uk/objects/uuid:971d5bfc-5a3a-4ea9-a4f4-e97b444243e1
Autor:
Martin S. Tallman, Peter H. Wiernik, Ian M. Franklin, Hillard J. Lazarus, H. G. Prentice, Alan Kenneth Burnett, Mark R. Litzow, G Harrison, Sue Richards, R Chopra, Jill Durrant, Jacob M. Rowe, Anthony H. Goldstone
In 1993 we initiated an International study in newly diagnosed adults with ALL (aged 15 to 55 years). 1508 eligible patients were entered before 31st October 2003 and achieved a complete remission (CR) rate of 91%. 551 patients underwent transplant i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b59e00279fc90a1decf9fbe8e3e974c0
https://ora.ox.ac.uk/objects/uuid:4a0bc2cb-4a88-43cb-850c-aff606b181e7
https://ora.ox.ac.uk/objects/uuid:4a0bc2cb-4a88-43cb-850c-aff606b181e7
Autor:
Rachel L. Harris, G. Reza Jalali, Frank Hill, Susan M. Richards, I. Jill Durrant, Ajay Vora, Christine J. Harrison, Tim O B Eden, Anthony H. Goldstone, Hazel M. Robinson, Zoë J. Broadfield, Kerry E. Barber, Sally E. Kinsey, M Martineau, Brenda Gibson, Ian Hann, Ian M. Franklin, Kan L. Cheung, Chris Mitchell, Anthony V. Moorman, John S. Lilleyman
Publikováno v:
British Journal of Haematology. 125:552-559
This study of children and adults with acute lymphoblastic leukaemia (ALL) is the largest series of patients with hypodiploidy (
Autor:
I. Jill Durrant, Wang Xin Victoria, Dan Douer, Elisabeth Paietta, Hillard M. Lazarus, David I. Marks, Ian M. Franklin, Andrew K McMilan, Selina M. Luger, Jacob M. Rowe, Mark R. Litzow, Martin S. Tallman, Georgina Buck, Rajesh Chopra, Chezi Ganzel, Susan M. Richards, Adele K. Fielding, Peter H. Wiernik, Anthony H. Goldstone
Publikováno v:
Blood. 126:795-795
This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and the Medical Research Counsel, United Kingdom, and supported in part by Public Health Service Grants CA18082
Autor:
Jacob M. Rowe, Mark R. Litzow, Alan Kenneth Burnett, Martin S. Tallman, Ian M. Franklin, Niculae Ciobanu, Jill Durrant, Selina M. Luger, Susan M. Richards, Georgina Buck, Elizabeth Paietta, Andrew McMillan, Adele K. Fielding, Peter H. Wiernik, Anthony H. Goldstone, R Chopra, Letizia Foroni, David I. Marks, H M Lazarus
Publikováno v:
Blood. 111(4)
An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy. Patients received 2 phase
Autor:
Martin S. Tallman, Adele K. Fielding, Selina M. Luger, Georgina Buck, Anthony H. Goldstone, David I. Marks, Mark R. Litzow, I. Jill Durrant, Hillard M. Lazarus, Ian M. Franklin, Susan M. Richards, Andrew McMillan, Rajesh Chopra, Jacob M. Rowe
Publikováno v:
Blood. 109(3)
Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993
Autor:
Martin S. Tallman, Peter H. Wiernik, Ian M. Franklin, Alan Kenneth Burnett, Mark R. Litzow, Susan M. Richards, I. Jill Durrant, Georgina Buck, R Chopra, Hillard M. Lazarus, Jacob M. Rowe, Lucy Cook, Anthony H. Goldstone
Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear. We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase. Patients up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8255967f2752b65644a8838a8c9e71f
https://europepmc.org/articles/PMC1895498/
https://europepmc.org/articles/PMC1895498/
Autor:
Christine J, Harrison, Anthony V, Moorman, Zoë J, Broadfield, Kan L, Cheung, Rachel L, Harris, G, Reza Jalali, Hazel M, Robinson, Kerry E, Barber, Sue M, Richards, Christopher D, Mitchell, Tim O B, Eden, Ian M, Hann, Frank G H, Hill, Sally E, Kinsey, Brenda E S, Gibson, John, Lilleyman, Ajay, Vora, Anthony H, Goldstone, Ian M, Franklin, Jill, Durrant, Mary, Martineau
Publikováno v:
British journal of haematology. 125(5)
This study of children and adults with acute lymphoblastic leukaemia (ALL) is the largest series of patients with hypodiploidy (
Publikováno v:
Hematology/oncology clinics of North America. 14(6)
Overall, the MRC Adult Leukaemia Trials have been successful, in that since the 1970s they have demonstrated a stepwise improvement in outcome. Examination of the survival curves shows the DFS rate at 5 years in UKALL Trial 1 of 5% rising to 38% in U